The regulatory environment for live biotherapeutic products is still uncertain globally, of course, but one booming area is the manufacturing of these products as they move through their clinical development process.
Adrien Nivoliez, CEO of Biose Industrie reflects on the challenges and success of 2020 and of the future of the Microbiome Therapeutics Industry, as well as the company’s growth in CDO business, the inception of new Clinical Drug product lines, a World First GMP production at 3500L, fundraising and the opening of a new office in Boston.
